{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:48:22Z","timestamp":1785750502979,"version":"3.56.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["R01 CA226436"],"award-info":[{"award-number":["R01 CA226436"]}]},{"DOI":"10.13039\/100016764","name":"Fred and Pamela Buffett Cancer Center","doi-asserted-by":"crossref","award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"10.13039\/100016764","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Office of Graduate Studies at the University of Nebraska Medical Center"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/13543776.2026.2699768","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:44:14Z","timestamp":1783079054000},"page":"743-755","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020\u2013present)"],"prefix":"10.1080","volume":"36","author":[{"given":"Alfie M.","family":"Case","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole A.","family":"Mack","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Trippier","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]},{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]},{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02138"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2018.07.002"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.05.012"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.12.022"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09697-6"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00163"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1378292"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00947"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118490"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00213"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116193"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115013"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00050"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c03035"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-23-0235"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-1335"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.02.067"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.275"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115515"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194877"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2014.03.015"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.08.002"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215417"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.5c00757"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.09.008"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-024-01177-4"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.10.009"},{"issue":"2","key":"e_1_3_4_31_1","first-page":"505","article-title":"The Aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-Cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs","volume":"63","author":"Desmond JC","year":"2003","unstructured":"Desmond JC, Mountford JC, Drayson MT, et al. The Aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-Cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 2003;63(2):505\u2013512.","journal-title":"Cancer Res"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.11.004"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020286"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2008.10.024"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00159"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3920"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2025.106729"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2025.2605012"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.04.027"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000122"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.01.026"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-1593"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.09.042"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.039099"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1379503"},{"key":"e_1_3_4_46_1","unstructured":"Linnanen T Hirvela L Illikainen K et al. Inventors novel heterocyclic compounds compositions methods of preparation and uses thereof patent WO2022\/234193A1. 2022."},{"key":"e_1_3_4_47_1","unstructured":"Koppitz M Siebeneicher H Steuber H et al. inventors [(Phenylsulfonyl)octahydro - EPI Minoisoindol - YL] (1H-1 2 3-Triazol-5 ylmethanones patent US2020\/0085791A1. 2020."},{"key":"e_1_3_4_48_1","unstructured":"Trippier P Maddeboina K Jonnalagadda S. Inventors inhibitors of AKR1C3 and methods of use patent WO2024\/030627A1. 2024."},{"key":"e_1_3_4_49_1","unstructured":"Trippier P Carmona A. Inventors AKR1C3 targeted heterobifunctional small molecule proteolysis targeting chimeras patent WO2024\/035780A1. 2024."},{"key":"e_1_3_4_50_1","unstructured":"Koppitz M Siebeneicher H Steuber H et al. inventors [8-(phenylsulfonyl)-3 8-diazabicyclo[3.2.1]oct-3-yl](1H-1 2 3-triazol-4-yl)methanones patent WO2017\/202817 A1. 2017."},{"key":"e_1_3_4_51_1","unstructured":"Koppitz M Siebeneicher H Steuber H et al. inventors [4-(phenylsulfonyl)piperazin-1-yl](1H-1 2 3-triazol-4-yl)methanone patent US2020\/0079758 A1. 2020."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10192"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.12.007"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.12.081"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00732"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-18-1322"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15831"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0015"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3369"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00112-0"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01126"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0223"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00740"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1665-9_5"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2012.01535.x"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_4_67_1","unstructured":"Adair C Chen T Ding J et al. Inventors TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS patent WO2021\/005586 A1. 2021."},{"key":"e_1_3_4_68_1","unstructured":"Wang T Ding Q Li F. Inventors PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF patent WO2024\/078392 A1. 2024."},{"key":"e_1_3_4_69_1","unstructured":"Lubika D Mutz M Zhu Y. Inventors CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR patent WO2024\/023666A1. 2024."},{"key":"e_1_3_4_70_1","unstructured":"Fryer C Kattenhorn L McLaughlin ME et al. Inventors methods of tricyclic AKR1C3 dependent kars inhibitor dosing field of the invention patent WO2024\/023641. 2024."},{"key":"e_1_3_4_71_1","unstructured":"Duan J Meng F Qi T et al. Inventors USE OF AKR1C3-ACTIVATED COMPOUND patent US2024\/0316069 A1. 2024."},{"key":"e_1_3_4_72_1","unstructured":"Li F Lin J Wang T et al. Inventors phosphoramidate macrocycle compounds and uses thereof patent WO2025\/214434 A1. 2025."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.363"},{"key":"e_1_3_4_74_1","unstructured":"Duan J-X Cao Y Cai X et al. Inventors DNA ALKYLATING AGENTS patent WO2016\/145092\/A1. 2016."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0130-5"},{"key":"e_1_3_4_76_1","unstructured":"Meng F Qi T Duan J et al. Inventors method for treating cancer by combining alkylating agent prodrug and cell cycle inhibitor patent EP4529926A1. 2025."},{"key":"e_1_3_4_77_1","unstructured":"Nilsson J. Inventor method for determining risks associated with hormone-dependent cancers patent WO2023\/153998A1. 2023."},{"key":"e_1_3_4_78_1","unstructured":"Xie Y Meng F Duan J et al. Inventors AKR1C3 detection method and diagnostic kit for detecting AKR1C3 and use therof patent US2024\/0142453A1. 2024."},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13060167"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2699768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2699768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2699768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:33:57Z","timestamp":1785749637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2699768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/13543776.2026.2699768"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2699768","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}